Andrew M. Ackrill

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Donald M. Jensen, Timothy R. Morgan, Patrick Marcellin et al. · Hepatology · 2006 · 469 citations · Full text

Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA.

Graham R. Foster, Andrew M. Ackrill, Robert Goldin et al. · Proceedings of the National Academy of Sciences · 1991 · 160 citations · Full text

Viral Replication, Immunology, Hepatitis B +18

Peginterferon alfa-2A (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose

S. Hadziyannis, Hugo Cheinquer, Timothy M. Morgan et al. · Journal of Hepatology · 2002 · 133 citations

Medicine, Phase Iii, Clinical Trials +9

Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene

Andrew M. Ackrill, Graham R. Foster, Carl Laxton et al. · Nucleic Acids Research · 1991 · 117 citations · Full text

Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial

Deepali Kumar, Michael G. Ison, Jean‐Paul Mira et al. · The Lancet Infectious Diseases · 2022 · 100 citations

Superiority Trial, Baloxavir Marboxil, Antiviral Drug Development +6